MC-Gly-Gly-Phe-Gly-GABA-Exatecan

MC-Gly-Gly-Phe-Gly-GABA-Exatecan ADC 是药物连接子偶联物，含有 IC50 为 22 μM 的拓扑异构酶 Exatecan。MC-Gly-Gly-Phe-Gly-GABA-Exatecan 靶向多种抗体，在体外和体内表现出细胞毒性和抗肿瘤功效。 在溶剂中：-80°C，6个月-20°C，1个月（密封储存，远离水分和光线） 体外研究： MC-Gly-Gly-Phe-Gly-GABA-Exatecan (0-10 μM) 通过靶向 CD30，CD33，CD70 和 B7-H3 抗体，在细胞 SR (CD30 阳性)，HL60 (CD33 阳性)，U251 (CD70 阳性) 和 Calu-6 (B7-H3 阳性) 中表现出细胞毒性。 体内研究： MC-Gly-Gly-Phe-Gly-GABA-Exatecan (10 mg/kg，静脉注射，每周一次，共 2 周) 在 A375 异种移植小鼠体内表现出抗肿瘤活性。 MC Gly Gly Phe Gly GABA Exatecan ADC is a drug linker conjugate containing the topoisomerase Exatecan with an IC50 of 22 μ M. MC Gly Gly Phe Gly GABA Hexatecan targets multiple antibodies and exhibits cytotoxicity and anti-tumor efficacy in vitro and in vivo. In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) In vitro studies: MC Gly Gly Phe Gly GABA Hexatecan (0-10 μ M) exhibits cytotoxicity in SR (CD30 positive), HL60 (CD33 positive), U251 (CD70 positive), and Calu-6 (B7-H3 positive) cells by targeting CD30, CD33, CD70, and B7-H3 antibodies. In vivo studies: MC Gly Gly Phe Gly GABA Hexatecan (10 mg/kg, intravenous injection, once a week for 2 weeks) showed anti-tumor activity in A375 xenograft mice.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet